HI
CCXI

Harbour Investments’s ChemoCentryx, Inc. CCXI Stock Holding History

Harbour Investments’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-81
Closed -$1K – 3950
2021
Q3 		$1K Buy
81
+33
+69% +$514 ﹤0.01% 3671
2021
Q2 		$1K Sell
48
-1
-2% -$25 ﹤0.01% 3714
2021
Q1 		$3K Buy
+49
New +$2.95K ﹤0.01% 3161

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Harbour Investments's CCXI Position: Q4 2021 in Review

Harbour Investments sold out of ChemoCentryx, Inc. (CCXI) in Q4 2021, closing a stake of 81 shares — an estimated $1K sold.

Harbour Investments first reported a position in CCXI in Q1 2021 and held it in 3 quarters. The position peaked at $3K in Q1 2021. 190 funds tracked by Wall St. Rank hold CCXI as of Q4 2021.

  • Harbour Investments reported no remaining ChemoCentryx, Inc. position as of Q4 2021 after selling out during the quarter.
  • Harbour Investments sold 81 ChemoCentryx, Inc. shares in Q4 2021, an estimated $1K.
  • Harbour Investments first reported a position in ChemoCentryx, Inc. in Q1 2021 and held it in 3 quarters.
  • Harbour Investments's ChemoCentryx, Inc. position peaked at $3K in Q1 2021.
  • 190 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2021.

Based on Harbour Investments's 13F filing for Q4 2021, filed 16 Feb 2022.